Pear Therapeutics Announces First Patient Dosed in Part II of Pear-006 Feasibility Study to Treat Depressive Symptoms in People with Multiple Sclerosis

Pear Therapeutics, Inc. today announced the first patient dosed in part II of the first clinical study evaluating Pear-006, a digital therapeutic product candidate for addressing depressive symptoms in Multiple Sclerosis (MS). The randomized controlled trial will enroll approximately 30 patients with Relapsing MS for eight weeks treatment with digital therapy and evaluate dosing, patient use, engagement, and other clinical outcomes.